Octave: Funding, Investors & Team (Sep 2026)
Octave, a developer specializing in clinical platforms, aims to revolutionize multiple sclerosis care through the generation, analysis, and integration of data. Their platform offers a comprehensive approach to reduce the overall cost of care by optimizing the utilization of healthcare medications and treatments. This also enables pharmaceutical companies to enhance the entire process of drug discovery, development, clinical trials, and post-marketing activities, all backed by real-world evidence.
Octave has raised $69.5M across 2 funding rounds on record, the most recent an undisclosed round of $39.5M announced in Nov 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Octave Company Profile and Key Stats
Latest funding round on record: Nov 2023.
Octave Funding Rounds
Octave raised $30.0M in a Series B announced in Jul 2023.
4 months later, an undisclosed round of $39.5M was announced in Nov 2023.
Octave Founders and Leadership Team
Contact details for the Octave team: 1 of 2 have an email address on file.
Start 14-day free trial →Octave Funding Compared to Other Biotechnology Startups
Octave's latest round of $39.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Octave in Biotechnology and Menlo Park
Companies Similar to Octave
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Octave Funding FAQs
What does Octave do?
Octave, a developer specializing in clinical platforms, aims to revolutionize multiple sclerosis care through the generation, analysis, and integration of data. Their platform offers a comprehensive approach to reduce the overall cost of care by optimizing the utilization of healthcare medications and treatments. This also enables pharmaceutical companies to enhance the entire process of drug discovery, development, clinical trials, and post-marketing activities, all backed by real-world evidence.
How much funding has Octave raised?
Octave has raised $69.5M across 2 rounds on record. The most recent is an undisclosed round of $39.5M announced in Nov 2023.
When did Octave last raise funding?
Octave's most recent funding round on record is an undisclosed round of $39.5M, announced in Nov 2023.
Who founded Octave?
FundedIQ lists Melinda Thomas (Founder) at Octave.
Who is the CEO of Octave?
William Hagstrom is listed as CEO at Octave.
Where is Octave headquartered?
Octave is based in Menlo Park, California, United States.
How many employees does Octave have?
Octave is in the 51-100 employee band.
How does Octave's funding compare to other Biotechnology startups?
Octave's latest round of $39.5M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Octave Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Octave is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.